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Summary Receptors for granulocyte colony-stimulating factor (G-CSFRs) have been confirmed on the cell surfaces of several non-
haematopoietic cell types, including bladder cancer cells. This observation has naturally led to the hypothesis that the expression of G-CSFR
on these cells may enhance their growth by G-CSF. In this study, the expression of G-CSFR was determined in both established human
bladder cancer cell lines and primary bladder cancers. We studied five different human bladder cancer cell lines (KU-1, KU-7, T-24, NBT-2
and KK) and 26 newly diagnosed bladder tumours. G-CSFR mRNA expressions on cultured cell lines were determined using the reverse
transcriptase polymerase chain reaction (RT-PCR) method. Furthermore, the G-CSFR binding experiments on the cultured cell lines were
conducted using the Na1251-labelled G-CSF ligand-binding assay method. Moreover, the G-CSFR mRNA expressions on primary bladder
tumour specimens were assessed using the in situ RT-PCR method. Three out of the five cultured cell lines (KU-1, NBT-2 and KK) exhibited
G-CSFR mRNA signals when the RT-PCR method was used. The G-CSFR binding experiments showed an equilibrium dissociation constant
(Kd) of 490 pM for KU-1, 340 pM for NBT-2 and 103 pM for KK cells. With in situ RT-PCR, the tumour cells of 6 out of 26 primary bladder tumour
specimens (23.1%) presented positive G-CSFR mRNA signals. Thus, in this study, G-CSFR expression was frequently observed on bladder
cancer cells. Therefore, the clinical use of G-CSF for patients with bladder cancer should be selected with great care.
Keywords: bladder cancer; granulocyte colony-stimulating factor receptor; in situ reverse transcriptase polymerase chain reaction; cell
growth promotion
Granulocyte colony-stimulating factor (G-CSF) is a peptide
hormone known to be responsible for the in vitro and in vivo
proliferation ofbone marrow progenitor cells into mature differen-
tiated cells (Demetri et al, 1991). This growth factor has had a
major impact on the management of patients with granulocyto-
penias and has also been extensively used as an adjunct to the
management of patients with haematological and non-haemato-
logical malignancies, either with or without prior intensive
chemotherapy (Gabrilove etal, 1988a, 1988b; Morstyn etal, 1988;
Ohno et al, 1990; Crawford et al, 1991; Gabrilove, 1991).
Meanwhile, G-CSF receptors have been noted to be present on
such cells as myeloblasts and mature neutrophils (Nicola et al,
1985). The receptors for G-CSF have also been demonstrated and
studied on a variety of other cells, including human myeloid
leukaemic cells (Begley et al, 1987) and leukaemic cell lines (Park
et al, 1989), human placenta and trophoblastic cells (Uzumaki et
al, 1989), human vascular endothelial cells (Bussolino et al, 1989)
and cell lines derived from human small-cell carcinoma of the
lung (Avalos et al, 1990) and the bladder (Tachibana et al, 1995).
Such G-CSF receptor expression on tumour cells has naturally
led to the tempting speculation that the administration of G-CSF
may enhance the proliferation of these particular cells. These
considerations thus prompted us to analyse the expression of
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G-CSF receptor on human bladder cancer cells, as systemic
administration of G-CSF is sometimes performed for this disease
in conjunction with chemotherapy.
MATERIALS AND METHODS
Cell lines
Five different cell lines derived from human transitional cell carci-
nomaofthe bladderwere used (Table 1): KU-1, KU-7, T-24, NBT-2
(Tachibana, 1982) and KK (Tachibana et al, 1995), and the charac-
teristics ofthe cell lines have all been reported previously.
Reverse transcriptase polymerase chain reaction
(RT-PCR)
The G-CSF receptor mRNA expressions on each of the cultured
cancer cells were studied using the reverse transcriptase poly-
merase chain reaction (RT-PCR) method. Total RNA samples
Table 1 Histological characteristics of five cell lines derived from human
transitional cell carcinoma of the bladder. TCC, transitional cell carcinoma.
Cell line Histological type Histological grade
KU-1 TCC 2
KU-7 TCC 1
T-24 TCC 3
NBT-2 TCC 3
KK TCC 3
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were purified from the cultured cancer cells using the acid guani-
dine phenol chloroform method (Chomozynski et al, 1987). The
RNA (5 jg) samples were converted into cDNA using oligo (dT)
primers and reverse transcriptase (code 8089SA, Gibco BRL
diluted with water to obtain 100 p1 of the cDNA preparation).
Five-microlitre samples were subjected to the following PCR.
(a) The 0-actin-specific fragment was detected by PCR of20
cycles at 94°C for 1 min, 65°C for 1 min and 72°C for 3 min
with primers 5'-GATATCGCCGCGTCGTCGTCGAC-3'
(forward primer) and 5'-CAGGAAGGAAGGCTGGAA-
GAGTGC-3' (reverse primer).
(b) the G-CSF receptor a chain 340-bp fragment was found by
PCR of35 cycles at 94°C for 1 min, 65°C for 1 min and 72°C
for 1 min with 5'-AAGAGCCCCCTTACCCACTACACC-
ATCTT-3' (forward primer) and 5'-TGCTGT-
GAGCTGGGTCTGGGACACTT-3' (reverse primer).
To confirm that the amplified products originated from their
corresponding cDNAs, they were then subjected to the appropriate
restriction enzyme digestion. In addition, each RT-PCR was
performed without processing the reverse transcriptase reaction as
a negative control.
The G-CSF receptor binding experiment was conducted as
follows. Na'251 (Dupon NEN) and enzymo-bead reagent (Bio-Rad)
were used. Recombinant mutant G-CSF (KW-2228), kindly
provided by Kyowa Hakko Kogyo, Japan, was employed as the
ligand. KW-2228 was radioiodinated with 37 MBq of Na'251 by
using the solid-phase glucose oxidase-lactoperoxidase method as
described by Piao et al (1990). The specific activity of radio-
iodinated KW-2228 was 6 x 106 c.p.m. jg-' protein. The cultured
cells were incubated for 24 h at 4°C in 24-well tissue culture plates
in 0.5 ml of isotonic phosphate-buffered saline (PBS) containing
0.2% bovine serum albumin and 125I-labelled KW-2228 with or
without KW-2228. Following incubation for 24 h, the medium was
aspirated, and the cells were washed with cold PBS. The cells were
then solubilized in 0.25 ml of 2M sodium hydroxide, and the
radioactivities were measured. Non-specific binding was measured
in the presence ofG-CSF at 1000 ng per0.5 ml. The Scatchard plot
of the specific binding of '251-labelled KW-2228 to the cells was
then estimated to obtain the affinity and receptor numbers.
The stimulation of cultured cancer cells by exogenous G-CSF
administration under serum-free conditions was studied. To main-
tain and subculture these cell lines under serum-free condition, we
needed some preparation and modification ofcell cultures. First of
all, these cells were subcultured with gradient degrees of lower
serum supplementations and then were finally subcultured in a
serum-free medium with the supplementation of transferrin and
insulin (insulin-transferrin-sodium selenite media supplement,
Sigma). After completing the preparation, these cells can be main-
tained and subcultured under serum-free conditions. Theestimated
viability of these cells under serum-free conditions by the trypan-
blue dye exclusion method was more than a 83% viability
(maximum 97.9%), which was not different from the serum
supplement conditions. The proliferating activity of the cultured
cancer cells was measured using a flow cytometric bromodeoxy-
uridine incorporation technique as previously described elsewhere
(Tachibana et al, 1995). Briefly, the 3 x 104 cells were incubated in
1 ml of RPMI 1640 medium (Gibco BRL) without serum supple-
mentation in 12-well culture dishes (Corning, New York; well
diameter 22 mm) at 37°C in a humidified atmosphere of
5% carbon dioxide with 95% air. Recombinant mutant human G-
CSF was added at a final concentration of 0.5 jg ml-' every 24 h
for a total ofthree times. Twenty-four hours after the final G-CSF
treatment (72 h after cell culture), bromodeoxyuridine was added
to each culture well at a final concentration of 5 jg ml-', and then
the incubation was continued for a further 1 h. The cells were
harvested with 0.25% trypsin with 1 mM ethylenediaminetetra-
acetic acid (EDTA) and were then washed twice. The cells were
subsequently stained by fluorescein isothiocyanate (FITC)-labelled
anti-bromodeoxyuridine antibody and then post-stained by 0.5%
propidium iodide. The double-stained cells were analysed by an
Epics Elite flow cytometer (Coulter, USA), and the labelling index
(LI), i.e. the number of cells stained by bromodeoxyuridine
divided by the total estimated cell count, was calculated.
Next, the same experiments were carried out using the
[3H]thymidine incorporation method. The serum-free subclone
cells (1 x 104) were incubated in 0.1 ml of the culture medium
without fetal calf serum (FCS) in a 96-well microtitre tray
(Nunc, Denmark). Recombinant G-CSF was added every 24 h at a
final concentration of 0.5 jg ml-' for a total of three times to the
cell cultures. Twenty-four hours after the final G-CSF treatment,
DNA synthesis in the cultures was determined by the addition
of [methyl-3H]thymidine (Amersham, UK) (0.6 jiCi per well;
1 Ci=37 MBq) during a 4-h pulse. The cells were then harvested
onto glass fibre filters and counted by liquid scintillation counter
(LS 9800, Beckman Instruments, USA).
All data are expressed as the mean ± s.d. The difference was
determined by Student's t-test (two-tailed) and P <0.05 was
regarded as statistically significant.
Tumour tissues specimens
Twenty-six tumour tissue specimens from patients with histologi-
cally confirmed transitional cell carcinoma ofthe bladder were used
in this study. Both normal tissue and tumour samples were obtained
by transurethral cold-cup biopsy technique from each patient.
Frozen sections cut at 5 jm were fixed with Streck Tissue Fixative
(STF, Streck Laboratories, Omaha, NE, USA) for 5 min before
processing for the in situ detection ofG-CSF receptor mRNA.
In situ detection of G-CSF receptor mRNA signals by
RT-PCR
The in situ RT-PCR detection of G-CSF receptor mRNA on
tumour samples was performed according to the modified method
as described by Nuovo et al (1995).
Briefly, frozen sections following STF fixation were digested
with proteinase K at 30 jg ml-' in 20 mm Tris-HCl, pH 7.4, for
5 min. The tissue specimens were then treated overnight with an
RNAase-free DNAase solution made according to the manufac-
turer's recommendations at 37°C. The tissue specimens were incu-
bated directly on a glass slide at 42°C for 30 min with 10 jil of a
solution containing the downstream primer (1 jM) and reverse
transcriptase (5 units; RT-PCR Kit, Perkin Elmer, Norwalk, CT,
USA). Each case was analysed for the expression of G-CSF
receptor transcripts. The sequences of the primer used for the
detection ofthe corresponding cDNA was previously described in
the section covering the RT-PCR method.
The solution for the amplification of the cDNA contained
4.5 mm magnesium chloride, 200 jM each of dATP, dCTP, dGTP
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and dTTP (for digoxigenin), 1 ,UM of each primer, 100 ,ug ml-1 of
BSA and 5 units Taq polymerase (Perkin Elmer) per 40 gi of
amplifying solution. Digoxigenin dUTP was used as the reporter
molecule. The concentration of digoxigenin in the amplifying
solution was 10 gM. The digoxigenin-labelled PCR product was
detected after incubation with an alkaline phosphatase-antidigoxi-
genin conjugate (1:200 dilution in 0.1 M Tris-HCl, pH 7.4) and
0.1 M sodium chloride for overnight at 37°C. Staining develop-
ment was then performed using chromagen nitroblue tetrazolium
and 5-bromo-4-chloro-3-indol-phosphate for 5 min. The PCR
reaction was performed with an initial denaturing step of94°C for
3 min followed by 25 cycles of annealing extension at the same
temperatures and times as previously described in the section
concerning the RT-PCR for the G-CSF receptor.
One essential aspect of this protocol is that the negative and
positive controls can be performed on the same glass slide along
with the experimental analysis. The positive control for in situ
PCR eliminates the DNAase digestive reaction. An intense nuclear
signal is generated from the target-specific amplification, DNA
repair and mispriming. This control demonstrates that the PCR
reaction and the subsequent detection steps all worked success-
fully. A prerequisite for the successful amplification of any given
cDNA is not a true positive control for the G-CSF receptor mRNA
but rather an intense signal with the in situ RT-PCR-positive
control. The negative control constitutes in situ RT-PCR in which
the tissue is treated with DNAase and the RT step is eliminated.
The absence of a signal thus demonstrates that amplification of
genomic DNA does not occur. The results for G-CSF receptor
signal expressions were read blindly by J-IH (a pathologist) and
MT and AM (urologists). If any obviously positive signal expres-
sions were observed on the tumour cells, the results were desig-
nated as positive. On the other hand, if no definitively positive
signal expressions were seen on the tumour cells, then the results
were defined as negative. When all three examiners agreed with
the positive and/or negative results, the final results were thus
defined as positive (+) and/or negative (-). However, when the
results differed among the examiners, the final results were desig-
nated as inconclusive (±).
RESULTS
G-CSF receptor m-RNA expressions ofthe cultured cancer cell lines
were studied using the RT-PCR method. The RT-PCR productexhib-
ited a specific G-CSF receptor transcription signal of 340 bp in the
samples from the cultured cells ofKU-1, NBT-2 and KK (Figure 1).
Binding studies using radiolabelled recombinant G-CSF
demonstrated the presence of high-affinity G-CSF binding recep-
tors on the cultured cancer cell lines of KU-1, NBT-2 and KK.
Non-specific binding, which ranged between 5% and 22%, was
subtracted from the total binding to determine the specific binding.
The Scatchard plot of the specific binding of '251-labelled KW-
2228 to the cell lines indicated that the cells harbour a single type
of G-CSF receptor (Figure 2). The Bmax calculated from the
Scatchard plots were 3140, 4010 and 458 molecules per cell for
KU-1, NBT-2 and KK respectively. The equilibrium dissociation
constants (Kd) of KU-1, NBT-2 and KK were 490 pM, 340 pM and
103 pM respectively.
The results of exogenous G-CSF stimulation obtained by both
flow cytometric BrdUrd labelling and [3H]thymidine incorporation
methods are listed in Table 2.
Figure 1 Detection of G-CSF receptor mRNA expressions of the cultured
cancer cell lines by RT-PCR method. The RT-PCR product exhibited a
specific G-CSF receptor transcription signal of 340 bp in samples from the
cultured cells of KU-1 (A), NBT-2 (B) and KK (C). N, negative control by
minus reverse transcriptase PCR; M, markers; P, positive control; A, KU-1;
B, NBT-2; C, KK. Size markers from top, 2,072, 1,500, then every 100 bp
BF
0.3
B
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Figure 2 Scatchard plot analyses of the specific binding of 1251-labelled
recombinant G-CSF to the cultured cell lines. The Bmm values, obtained from
the intercept of the slope with the abscissa on the Scatchard plots,
were 490 pM, 340 pM and 103 pM for KU-1, NBT-2 and KK respectively.
B/F, bound-free ratio
The BrdUrd labelling of KU-1, NBT-2 and KK at 72 h after
initial incubation with 0.5 ,ug ml-' G-CSF were 31.2 ± 2.1% in
KU-1, 22.5 ± 3.8% in NBT-2, 18.8 ± 2.2% in KK, 11.2 ± 1.2% in
KU-7 and 15.8 ± 1.9% in T-24. The BrdUrd labelling of KU-1,
NBT-2 and KKwith G-CSF were significantly higherthan those of
controls (without G-CSF administration), i.e. 21.3 ± 2.4% in
KU-1, 16.5 + 3.1% in NBT-2 and 11.4 + 1.8% in KK
(P <0.01). However, KU-7 and T-24 did not demonstrate any
increased BrdUrd labelling when compared with the controls i.e.
10.5 ± 1.2% in KU-7 and 16.7 ± 2.5% in T-24.
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Table 2 The results of exogenous G-CSF stimulation obtained by both flow cytometric bromodeoxyuridine (BrdUrd) labelling and [3H]thymidine incorporation
methods.
BrdUrd labelling (Z) [3H]Thymidine incorporation (c.p.m. per well)
Control G-CSF stimulation Control G-CSF stimulation
KU-1 21.3 ± 2.4 31.2 ± 2.1** 6168.0 ± 441.8 6900.3 ± 308.4*
NBT-2 16.5 ± 3.1 22.5 ± 3.8* 5004.4 ± 218.2 5483.8 ± 302.7*
KK 11.4 ± 1.8 18.8 ± 2.2** 4475.2 ± 213.3 5217.3 ± 480.9**
KU-7 10.5 ± 1.2 11.2 ± 1.2 4057.8 ± 216.2 4089.5 ± 306.2
T-24 16.7 ± 2.5 15.8 ± 1.9 5353.2 ± 249.6 5308.0 ± 458.3
The BrdUrd labelling of KU-1, NBT-2 and KK at 72 h after initial incubation with 0.5 9g ml-' G-CSF were 31.2 + 2.1% in KU-1, 22.5 ± 3.8% in NBT-2,
18.8 ± 2.2% in KK, 11.2 ± 1.2% in KU-7 and 15.8 + 1.9% in T-24. The BrdUrd labelling of KU-1, NBT-2 and KK with G-CSF were significantly higher than those
of controls (without G-CSF administration) (21.3 + 2.4% in KU-1, 16.5 ± 3.1% in NBT-2 and 11.4 ± 1.8% in KK) (P< 0.05). However, KU-7 and T-24 did not
demonstrate any increased BrdUrd labelling when compared with the controls (10.5 ± 1.2% in KU-7 and 16.7 +2.5% in T-24). In addition, exactly the same
results were also obtained using the [3H]thymidine incorporation method. KU-1, NBT-2 and KK cells exhibited higher [3H]thymidine incorporations than those
without G-CSF stimulation. The differences were also statistically significant (P<0.05 for KU-1 and NBT-2, P<0.01 for KK). BrdUrd, bromodeoxyuridine; G-CSF,
granulocyte colony-stimulating factor; c.p.m., count per minute; *P<0.05; **P<0.01.
In addition, exactly the same results were also obtained using
the [3H]thymidine incorporation method. KU-1, NBT-2 and KK
cells exhibited higher [3H]thymidine incorporations than those
without G-CSF stimulation. The differences were also statistically
significant (P<0.05 for KU-I and NBT-2, P<0.01 for KK).
Twenty-six cases ofhuman bladder cancer were included in this
study and their salient pathological data and the presence or
absence ofexpression ofG-CSF receptor mRNA signals obtained
by in situ RT-PCR are also provided in Table 3. With in situ RT-
PCR, the tumour cells of 6 of the 26 bladder tumour specimens
(23.1%) had a positive G-CSF receptor mRNA signal. On the
other hand, 17 tumour specimens demonstrated negative signals in
three specimens, thus resulting in inconclusive findings (±).
The G-CSF receptor expressions on five different cultured cell
lines were also determined using the in situ RT-PCR method.
Three out ofthe five cultured cell lines (KU-1, NBT and KK) also
exhibited positive results for the G-CSF receptor mRNA signals,
the same as for the conventional RT-PCR method. Figure 3A
demonstrates the detection of G-CSF receptor expression of
cultured cancer cells (KK) by the in situ RT-PCR method. The
signal in the nuclei ofmany ofthe cancercells for G-CSF receptor
was also noted. The signal was lost in the material when the
reverse transcriptase reaction step was omitted (Figure 3B).
Figure 4 presents an in situ RT-PCR specimen ofCase 3 and the
histological findings, classifying it as a grade 3, muscle-invasive
transitional cell carcinoma of the bladder (Figure 4A). The
papillary part ofthe tumour cells exhibited a strongly stained, rela-
tively homogenous pattern based on the in situ RT-PCR method
(Figure 4B). In addition, the submucosal tissue clearly demon-
strated negative staining.
It was also interesting to note that when the expression of
G-CSF receptor mRNA on tumour tissue was compared with the
histological tumour grades and stages, the staining results did not
correlate with the tumour grade or stage.
DISCUSSION
Although the incorporation of systemic chemotherapy in the treat-
ment of patients with invasive bladder cancer is becoming an
extremely important treatment modality, the majority of morbidi-
ties are from bone marrow suppression, which may be the main
Table 3 Summary of granulocyte colony-stimulating factor receptor
(G-CSFR) expression of human bladder cancer tissues determined by
in situ reverse transcriptase-polymerase chain reaction.
Case Grade Stage G-CSFR expression
1 3 pT3b +
2 2 pTlb +
3 3 pT3b +
4 2 pTlb +
5 2 pTla +
6 2 pTla +
7 3 pT4 -
8 2 pTla
9 3 pT3b -
10 3 pT4 -
11 2 pTa
12 3 pT3b -
13 3 pT4 -
14 2 pTla
15 2 pTla
16 1 pTla
17 3 pT4 -
18 2 pTlb -
19 2 pTla
20 1 pTla
21 2 pTlb -
22 2 pTla
23 3 pT2 -
24 2 pTlb +
25 2 pTla +
26 3 pT3b +
With in situ RT-PCR, the tumour cells of 6 of the 26 bladder tumour
specimens (23.1%) had a positive G-CSF receptor mRNA signal. On the
other hand, 17 tumour specimens demonstrated negative signals in three
specimens, thus resulting in inconclusive findings (±).
cause of the dose-limiting factor, resulting in a systemic relapse
(Scher, 1992). The availability of haematopoietic growth factors
has reduced the toxicities of the regimens currently in use. In the
earliest trial ofgranulocyte colony-stimulating factor and M-VAC
chemotherapy for the treatment of urothelial cancers, such as the
coadministration ofhaematopoietic growth factors associated with
combination chemotherapy, the treatment cycles with and without
the growth factor were compared in each individual. When the
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Figure 3 Detection of G-CSF receptor expression of cultured cancer cells (KK) by the in situ RT-PCR method. Note the signal in the nuclei of many of the cells
for G-CSF receptor (A, x 200). This signal was lost in the material if the reverse transcriptase step was omitted (B, x 200)
patients were able to receive full doses of the drugs scheduled at
interval days 14 and 21 (100% versus 29%), fewerdays (3 vs 32) of
neutropenia were observed, and the incidence ofmucositis was also
reduced with the coadministration of the G-CSF (Gabrilove et al,
1988b).
Subsequent studies have further confirmed the efficacy of
G-CSF in conjunction with systemic chemotherapy for advanced
bladder cancer patients (Aso et al, 1992; Miyanaga et al, 1994).
Therefore, reducing the toxicities ofthe chemotherapy ensures that
treatment recommendations will allow patients the maximal
opportunity for both a cure and the maintenance of their organ
functions, while, at the same time, minimizing the toxicities in
patients for whom systemic approaches are unwarranted.
Interestingly, it has been reported recently that G-CSF may
enhance tumour sensitivity to methotrexate in vitro (Ohigashi,
1990) and increase the sensitivity ofimplanted urothelial tumours
to chemotherapy in nude mice (Akaza et al, 1992). Furthermore, a
significantly additive inhibitory effect on the in vitro cell growth
of the human urothelial tumour cell line (EJ28) under the
combined administration of G-CSF and methotrexate has also
been reported (Block et al, 1993). These findings thus suggest an
expanded role for these agents. Furthermore, the high-dose
chemotherapy administered as part of bone marrow transplants
produces a prolonged aplastic period, entailing a high risk of
life-threatening status. In this regard, recombinant G-CSF has
been studied in patients undergoing autologous and allogeneic
transplants. In both autologous and allogeneic transplant settings,
G-CSF accelerated myeloid recovery compared with the historical
control (Masaoka et al, 1989; Taylor et al, 1989).
More recently, it has been shown that patients who are in need
of a bone marrow transplant but who cannot be harvested because
of bone marrow tumour involvement or pelvic radiation-induced
marrow injury may now undergo such transplants using stem cells
collected from the peripheral blood. Indeed, peripheral stem cell
transplants have been successfully performed in patients with
Hodgkin's disease, non-Hodgkin's lymphoma, myeloma and other
solid cancers, such as breast, ovarian and testis cancer and in chil-
dren with neuroblastomas (Kessinger et al, 1986, 1989; Juttner et
al, 1988; Fremand et al, 1989; Lasky et al, 1989). Therefore, the
application of G-CSF in combination with chemotherapy has
become widely accepted as a treatment modality.
It should be pointed out, on the other hand, that G-CSF receptor
expressions have been found on the surface of several non-
haematopoietic cell types, including human carcinoma cells
(Bussolino et al, 1989; Uzumaki et al, 1989; Avaros et al, 1990). In
fact, we previously reported that human transitional carcinoma cells
expressing G-CSF receptor generated an acceleration oftumour cell
proliferation (Ohigashi et al, 1992; Tachibana et al, 1995).
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Figure 4 Detection of G-CSF receptor expression in human cancertissues
by the in situ RT-PCR method. Haematoxylin and eosin staining of the tissue
(A, x 200). Note the signal in the nuclei of many of the cancer cells for
G-CSF receptor (B, x 200). This signal was lost in the serial section if the
reverse transcriptase step was omitted (C, x 200)
The above observations have naturally led to the tempting spec-
ulation that G-CSF systemic administration may provide growth
promotion for transitional carcinoma cells. Thus, the frequency of
G-CSF receptor expression on transitional cell carcinoma cells has
become an extremely significant factor with respect to the applica-
tion ofG-CSF in a clinical setting.
As was observed in this study, G-CSF receptor expressions were
frequently observed on human transitional carcinoma cells of the
bladder. However, the physiological significance of G-CSF recep-
tors on the surface of non-haematopoietic cells remains unclear.
Controversy exists concerning whether or not these G-CSF recep-
tors are similar to the receptors expressed on cells of neutrophilic
lineage, binding G-CSF with high affinity, and whether they are
present on the surface of these non-haematopoietic cell types in
sparse numbers (Bussolino et al, 1989; Uzumaki et al, 1989;
Avaros et al, 1990). Moreover, at present, five different human
G-CSF receptor isoforms or classes arising from alternative RNA
splicing have been isolated, which are all identical in the extracel-
lulardomainbutdiffer in theirdownstream sequences (Avalos et al,
1996). The physiological roles of the various human G-CSF
receptor isoforms and the regulation of their expression remain
unclear, although the class II soluble receptor may function to nega-
tively modulate responses to G-CSF by serving as anon-signalling
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sink that directly competes with the membrane-bound receptor
forms in a dose-dependent fashion for ligand binding, as has been
reported forthe soluble receptor for epidermal growth factor (Basu,
1996). In contrast, the class II receptor could positively modulate
the responses to G-CSFby serving as abinding protein that protects
G-CSF from degradation or clearance in the extracellular space,
similar to the growth hormone binding protein that has been shown
to prolong the overall half-life ofgrowth hormones (Veldhuis et al,
1993). Therefore, the expression ofG-CSF receptor does not neces-
sarily positively modulate the responses to G-CSF.
In line with these findings, our previous observation demon-
strated that the G-CSF-expressing bladder cancer cells exhibited
high-affinity binding to G-CSF and promoted the growth stimula-
tion ofcultured bladder cancer cells.
In addition, numerous studies have demonstrated that some
human bladder cancers may produce G-CSF frequently, presenting
leukaemoid reactions (Mizutani et al, 1995). Furthermore, G-CSF
production in vitro was demonstrated in another bladder cancer cell
line (5637) that is used as a source ofG-CSF (Bailly et al, 1995).
Taking all these things into consideration, G-CSF and its
receptor expression may therefore act in tumour cell paracrine
and/or autocrine loop mechanisms.
This observation therefore suggests that G-CSF may stimulate
the clonal growth of human bladder cancer cells by binding to its
specific receptors if these cells feature G-CSF receptors on the
surface. It should be pointed out, however, that this finding does
not diminish the efficacy of G-CSF administration in conjunction
with systemic chemotherapy, as chemotherapy does work
extremely well for such cancers as testis cancer and some
haematopoietic cancers.
At this time, we can only recommend that all bladder cancers
should be tested for the expression ofG-CSF receptor before using
G-CSF, because there is the possibility of growth promotion by
G-CSF ifthey have G-CSF receptor on their cell surfaces.
The in situ determination of the G-CSF receptor expression on
the surface of these cells may be difficult because the previous
technique using standard in situ hybridization is a far less sensitive
method than PCR techniques. It is obvious that greater sensitivity
can be obtained by employing the in situ RT-PCR technique than
by using standard RNA with in situ hybridization subsequent to
the 10- to 100-fold increase in the target copy number following
amplification (Mignatti et al, 1986; Nuovo et al, 1993). Therefore,
the significant advantages of this technique are its capabilities of
detecting very minute mRNA expression on the cells and in clari-
fying the exact source of the particular cells. Thus, this in situ
RT-PCR method is considered to be a useful technique for
studying the relationship between tumour behaviour and cytokine
and/or cytokine receptor expression.
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